7 Affordable Stocks With Good Earnings Growth for 2026

4. Halozyme Therapeutics, Inc. (NASDAQ:HALO)

EPS Diluted Growth (YoY): 56.68%

EPS Diluted Growth (FWD): 51.99%

Forward P/E: 11.01

Number of Hedge Fund Holders: 41

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best affordable stocks with good earnings growth for 2026. Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on December 18 that Johnson & Johnson received approval from the U.S. Food and Drug Administration (FDA) for RYBREVANT FASPRO, co-formulated with ENHANZE® for people with epidermal growth factor receptor (EGFR)-mutated locally advanced or metastatic non-small cell lung cancer. RYBREVANT FASPRO holds approval across all indications of RYBREVANT, and marks the first and only subcutaneously administered targeted therapy for patients with EGFR+ mNSCLC.

Management further reported that RYBREVANT FASPRO delivered a significant reduction in administration time from several hours to around five minutes when compared to intravenous delivery, and exhibited an approximately fivefold reduction in administration-related reactions; 13% in subcutaneous compared to 66% in intravenous arm. Dr. Helen Torley, president and chief executive officer of Halozyme Therapeutics, Inc. (NASDAQ:HALO), stated that RYBREVANT FASPRO holds the potential to make administration more convenient and faster for patients due to the company’s leading ENHANZE drug delivery technology.

In a separate development, Halozyme Therapeutics, Inc. (NASDAQ:HALO) received a rating update from TD Cowen on December 5, who reaffirmed a Buy rating on the stock with a $79 price target. However, Halozyme Therapeutics, Inc. (NASDAQ:HALO) was downgraded to Sell from Neutral by Goldman Sachs on December 4, with the firm setting a $56 price target. The firm told investors that a central debate for the company is the long-term value of its Enhanze royalty model, which faces a considerable post-2030 revenue cliff with around 70% of the royalties rolling off on the contract between 2030 and 2035. Typical business-development pacing appears inadequate to offset this trend, according to the firm.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical technology platform company that develops, manufactures, and commercializes drug-device combination products through advanced auto-injector technology. They offer commercial or functional benefits, including increased patient comfort and adherence, and enhanced tolerability and convenience.